Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the
efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for
patients with acute ischaemic stroke in 4.5-6 hours after stroke onset.
Phase:
Phase 3
Details
Lead Sponsor:
Tasly Biopharmaceuticals Co., Ltd. Tasly Pharmaceuticals, Inc.